ResMed RMD Accrued Contingent Liabilities
Accrued Contingent Liabilities at other companies
Other financials
Where this comes from
Reported directly by ResMed in its filing.
Tagged under the XBRL concept us-gaap:LossContingencyAccrualAtCarryingValue.
The source filing: ResMed’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 6:19 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000943819-26-000025
During the nine months ended March 31, 2026 and March 31, 2025, receivables sold with limited recourse were $150.4 million and $155.9 million, respectively. As of March 31, 2026, the maximum exposure on outstanding receivables sold with recourse and the associated contingent provision were $33.8 million and $0.8 million, respectively. As of June 30, 2025, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $34.1 million and $0.7 million, respectively.
Item 1. Financial Statements
FAQ
- What is ResMed's accrued contingent liabilities?
- ResMed (RMD) reported accrued contingent liabilities of $800K in Q1 2026.
- How has ResMed's accrued contingent liabilities changed year-over-year?
- ResMed's accrued contingent liabilities increased by 14.3% year-over-year, from $700K to $800K.
- What is the long-term trend for ResMed's accrued contingent liabilities?
- Over 3 years (2022 to 2025), ResMed's accrued contingent liabilities has grown at a -69.3% compound annual growth rate (CAGR), from $24.2M to $700K.
Ask your AI about ResMed's accrued contingent liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
